IBCCES is the global leader in training and certification for healthcare professionals, educators and corporate partners who work with individuals with autism and other cognitive disorders. Our reach extends to more than 2 million people in all 50 states and over 70 countries around the globe. IBCCES Member Learning Community is provided as a free service to all IBCCES members who have completed one or more of our training and certification programs.
Study reveals increased cannabis use in individuals with depression
The prevalence of cannabis, or marijuana, use in the United States increased from 2005 to 2017 among persons with and without depression and was approximately twice as common among those with depression in 2017. The findings, which are published in Addiction, come from a survey-based study of 728,691 persons aged 12 years or older.
“Perception of great risk associated with regular cannabis use was significantly lower among those with depression in 2017, compared with those without depression, and from 2005 to 2017 the perception of risk declined more rapidly among those with depression. At the same time, the rate of increase in cannabis use has increased more rapidly among those with depression,” said corresponding author Renee Goodwin, PhD, MPH, of Columbia University and The City University of New York.
The prevalence of past 30-day cannabis use among those with depression who perceived no risk associated with regular cannabis use was much higher than that among those who perceived significant risk associated with use (38.6% versus 1.6%, respectively).
Certain groups appeared more vulnerable to use. For instance, nearly one third of young adults (29.7%) aged 18-25 with depression reported past 30-day use.
In 2017, the prevalence of past month cannabis use was 18.9% among those with depression and 8.7% among those without depression. Daily cannabis use was common among 6.7% of those with depression and among 2.9% of those without.